New Blood-Based “Biological Age” Test May Predict Dementia Years Before Symptoms, Study Finds

LONDON — A large-scale study out of King’s College London suggests that a simple blood test, which gauges how “old” a person’s body appears compared with their calendar age, may help predict who will develop dementia—and roughly how soon—years before memory lapses or confusion appear. The work, based on plasma metabolites from more than 220,000 adults in the UK Biobank, adds a metabolomic “biological age” metric called MileAge delta to genetic risk scores. Published this month, the findings potentially open a new pathway for early-life dementia-risk stratification and targeted lifestyle interventions long before cognitive decline sets in.

Key Findings: What the Blood “Clock” Shows

Researchers led by Dr. Julian Mutz at King’s College London developed a metabolomic “ageing clock” that estimates biological age from 168 to 249 small molecules (metabolites) circulating in blood plasma. These metabolites reflect essential physiological processes such as energy production, nutrient breakdown, and systemic inflammation—cellular signals that shift predictably with age, lifestyle, and disease.

Using data from the UK Biobank, the research team analyzed plasma metabolite profiles in 223,496 adults who were initially cognitively healthy, tracking their neurological health over a multi-year follow-up period. Over time, 3,976 participants developed dementia, including 1,881 diagnosed with Alzheimer’s disease and 933 with vascular dementia.

The “clock” calculates a value called MileAge delta: the difference between a person’s metabolomic biological age and their chronological age.

• A positive MileAge delta means the body “looks” biologically older than the calendar suggests.

• A negative MileAge delta indicates a biologically younger profile.

Participants whose biological age exceeded their actual age by more than one standard deviation (representing about 16 percent of the sample) exhibited a 20 percent higher risk of developing any form of dementia over time. Notably, they faced a 60 percent higher risk of vascular dementia specifically, compared to peers whose biological ages matched or trended younger than their chronological years.

When the team combined the MileAge delta metric with the strongest common genetic risk factor for late-onset Alzheimer’s—the APOE ε4 allele—the results were striking. Individuals who possessed both advanced biological ageing and two copies of the APOE ε4 gene were up to ten times more likely to develop dementia than the average participant in the cohort.

How the Test Differs from Genetic Screening

Most clinical and public discussions surrounding dementia risk focus heavily on family history and inherited genetics. While genes like APOE ε4 raise lifetime susceptibility, they only explain part of the puzzle; they cannot predict exactly why or when some individuals succumb to the disease while others with the same genetic profile remain healthy.

The new metabolomic clock is not designed to replace genetic testing. Instead, it captures dynamic, real-time biological signals that genetics alone miss, such as long-term metabolic strain and cardiovascular stress.

“Genetics load the gun, but environment and lifestyle may pull the trigger,” notes one dementia epidemiologist not involved in the study, echoing commentary surrounding the publication.

By tracking metabolites that fluctuate based on diet, blood-sugar control, lipid profiles, and chronic inflammation, the MileAge clock flags individuals whose bodies are “ageing faster.” This provides a critical window for aggressive risk-factor management before irreversible brain damage occurs.

+-----------------------------------------------------------------------+
|                       THE DEMENTIA RISK PUZZLE                        |
+----------------------------------+------------------------------------+
|          GENETIC RISK            |          METABOLIC RISK            |
|       (Fixed at Birth)           |       (Dynamic & Modifiable)       |
+----------------------------------+------------------------------------+
| • e.g., APOE ε4 allele status    | • MileAge delta (Biological Age)   |
| • Establishes baseline tendency  | • Reflects diet, stress, and sleep |
| • Cannot track active progression| • Captures real-time inflammation  |
+----------------------------------+------------------------------------+

Which Metabolites Matter Most?

Among the more than 100 metabolites analyzed in the panel, glucose emerged as the single strongest individual predictor of future dementia risk, even after rigorous statistical correction for multiple testing. Elevated blood glucose is well-known to drive microvascular damage, systemic inflammation, and insulin resistance—factors that contribute directly to brain-small-vessel disease and Alzheimer’s-type pathology over several decades.

Other biological signals with variable but significant associations included:

• Branched-chain amino acids (BCAAs): Molecules involved in protein synthesis and metabolic regulation.

• GlycA: A novel biomarker for systemic inflammation tied to glycoprotein clusters on acute-phase proteins.

These findings hint at an intricate interplay between metabolic health, insulin signaling, and low-grade, chronic inflammation, which experts often describe as the shared “biological soil” from which cognitive decline grows.

Predicting When Dementia Might Appear

Beyond assessing whether someone might develop dementia, the metabolomic clock also signals when symptoms are likely to manifest. Individuals with a higher MileAge delta developed dementia earlier, on average, than those with younger biological ages—shifting the timeline forward not by months, but by years, across multiple dementia subtypes.

“This is one of the first large-scale demonstrations in apparently healthy mid-life adults that a metabolomic ageing clock can not only predict dementia risk but also approximate the age of onset,” said Dr. Julian Mutz, lead author and a research fellow at King’s College London’s Institute of Psychiatry, Psychology & Neuroscience.

However, researchers emphasize that the model does not yet provide precise, individual-level calendars. It remains a population-level risk-stratification tool rather than a definitive clinical crystal ball.

Expert Perspectives and Clinical Context

Independent medical experts have welcomed the innovative approach but emphasize that the test remains firmly within the research domain for now.

“This kind of blood-based biological age measure is a powerful epidemiological tool,” says Dr. Sarah L. Mackey, a neurologist and dementia researcher at a major U.S. academic center, who was not involved in the study. “It doesn’t diagnose dementia directly, but it can stratify risk in ways that might guide who receives closer monitoring or more intensive prevention efforts.”

Other specialists note that similar metabolic signals have appeared in earlier, independent research. A 2025 UK Biobank analysis of 249 metabolites similarly found that lipid-related markers, linoleic acid, sphingomyelin, glucose, and branched-chain amino acids ranked among the top predictors of all-cause dementia, Alzheimer’s disease, and vascular dementia.

Implications for Public Health and Prevention

The public health stakes are undeniably high. According to public health data, there are currently about 982,000 people living with dementia in the United Kingdom alone, with projections suggesting that figure could rise to 1.4 million by 2040 if current trends hold.

Globally, modeling by the World Dementia Council and other major health organizations estimates that up to 40 to 45 percent of dementia cases might be delayed or entirely prevented by aggressively addressing modifiable risk factors. These include mid-life hypertension, smoking, obesity, physical inactivity, low educational attainment, and type 2 diabetes.

       GLOBAL POTENTIAL FOR DEMENTIA PREVENTION
       
       [==================] 40-45% Modifiable Risk Factors
       (Hypertension, Obesity, Inactivity, Diabetes, Smoking)
       
       [========================] 55-60% Non-Modifiable / Unknown Factors
       (Fixed Genetics, Advanced Age)

A blood test capable of flagging accelerated biological ageing in mid-life could theoretically help clinicians deploy targeted interventions much earlier. For instance, a patient presenting with a positive MileAge delta and elevated glucose could be prioritized for intensive blood-pressure control, tailored statin therapy, structured exercise programs, and aggressive diabetes management decades before memory complaints begin.

“In the future, such clocks could be part of routine mid-life check-ups or could help select high-risk participants for prevention trials,” Dr. Mutz noted in a statement.

Limitations and Balancing the Promise

Despite the exciting data, the study carries several caveats that warrant caution:

1. Demographic Limitations: The findings relied on data from the UK Biobank, a cohort that is predominantly white, middle-aged to older, and relatively affluent. This limits how accurately these findings can be generalized to more diverse ethnic and socioeconomic populations globally.

2. Lack of Standardization: The metabolomic panel is complex and not yet standardized across commercial pathology laboratories. A cheap, widely available, and clinically validated test based on this specific model does not yet exist for primary care physicians.

3. Risk is Not Destiny: A higher biological age score is an indicator of statistical probability, not a certainty. Many individuals with an elevated MileAge delta or an APOE ε4 genetic profile will never develop dementia, while others with low risk scores will still experience cognitive decline.

Furthermore, current models cannot yet distinguish between Alzheimer’s disease, vascular dementia, and mixed pathology with absolute precision in a practical clinical setting. Experts strongly caution against the premature commercialization or direct-to-consumer marketing of “dementia-age” tests without rigorous regulatory validation.

“Tools like this are exciting, but they must be embedded in broader prevention strategies, not sold as standalone predictors of fate,” Dr. Mackey emphasized.

What This Means for Your Daily Health

For health-conscious readers, the takeaway is not to seek out an experimental blood test, but rather to double down on the modifiable lifestyle factors that overlap heavily with the metabolic biomarkers flagged in the study.

To support healthy cellular and brain ageing, public health authorities recommend focusing on these core areas:

• Monitor Metabolic Metrics: Keep blood pressure, cholesterol profiles, and blood sugar within optimal ranges. Address prediabetes-type blood glucose elevations early through dietary adjustments and medical guidance.

• Stay Physically Active: Engage in regular cardiovascular and strength-building exercises, which have been shown to lower systemic inflammation and improve insulin sensitivity.

• Prioritize Brain-Healthy Habits: Limit tobacco use, minimize alcohol consumption, ensure adequate sleep, and maintain a nutrient-dense, balanced diet.

If metabolomic ageing clocks eventually transition from clinical trials into routine check-ups, they will likely serve as a quantitative tool to help doctors and patients identify exactly who needs the most intensive lifestyle support.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.earth.com/news/blood-test-may-predict-dementia-years-before-symptoms-appear/